NovaBridge Biosciences (NBP) Total Current Liabilities (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Total Current Liabilities data on file, last reported at $26.9 million in Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $26.9 million, up 218.12% year-over-year; the trailing twelve-month figure through Dec 2025 was $26.9 million (up 218.12% YoY), and the FY2025 annual result was $26.9 million, up 218.12% from the prior year.
• Total Current Liabilities rose to $26.9 million in Q4 2025 per NBP's latest filing, from $16.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $97.6 billion in Q4 2021 and troughed at $7.3 million in Q2 2025.
• A 5-year average of $7.5 billion and a median of $26.9 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2021 and 2022: Total Current Liabilities soared 112170.09% in 2021, then plunged 99.89% in 2022.
• A 5-year view of Total Current Liabilities shows it stood at $97.6 billion in 2021, then sank by 99.89% to $106.6 million in 2022, then tumbled by 46.35% to $57.2 million in 2023, then slumped by 85.22% to $8.5 million in 2024, then soared by 218.12% to $26.9 million in 2025.
• Business Quant data shows NBP's Total Current Liabilities at $26.9 million in Q4 2025, $16.1 million in Q3 2025, and $7.3 million in Q2 2025.